Effects of angiotensin II receptor antagonist on endothelial vasomotor function and urinary albumin excretion in type 2 diabetic patients with microalbuminuria.

What Was Tested

This randomized controlled trial looks at Losartan.

Who Took Part

According to the abstract, 2 patients were involved.

The age groups tagged for this paper are adults and middle-aged adults, both men and women.

Endothelial function was measured in 80 type 2 diabetic patients with microalbuminuria and 68 non-diabetic controls using high-resolution vascular ultrasound.

How the Study Was Run

The design is described as randomized, double-blind and placebo-controlled.

Because people in this Losartan study were split into groups at random, differences between the groups are less likely to reflect who happened to join each one.

As a double-blind Losartan study, the assignments were hidden from both participants and investigators until the end.

Some patients received a placebo instead of Losartan, giving a reference point.

Urinary albumin excretion and endothelial function were assessed at baseline, 3 and 6 months.

What Was Measured

The subject headings attached to it are Albuminuria, Angiotensin Receptor Antagonists, Diabetes Mellitus, Type 2, Endothelium, Vascular, Losartan and Vasodilation.

What This Means in Plain Language

The paper is a randomized, double-blind and placebo-controlled study of Losartan in 2 patients.

With fewer than 40 people, it is a small study, so it is better read as an early signal for further research than as a settled answer.

The abstract goes on to report its results in about 8 sentences; this page does not restate them, so read the paper for the findings and their limits.

The publication is from 2002 (Diabetes/metabolism research and reviews), a journal based in England.

More context: all human trials.